FREEDOM Trial Demonstrates CRT Response Rates Using St. Jude Medical Optimization Feature are Comparable to Echo Optimization

ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced results of the FREEDOM trial during the late breaking clinical trial presentations at Heart Rhythm 2010, the Heart Rhythm Society’s 31st Annual Scientific Sessions. The trial demonstrated that the QuickOpt® optimization feature available in St. Jude Medical cardiac resynchronization therapy (CRT) devices produces an equivalent response rate in CRT patients as optimization using echocardiography (echo).